Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 20

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 20
---
 |

| · | our ability to staff and maintain our Los Angeles 
 production facility under fully compliant cGMP;   |

| · | the actions of our competitors and success of                        
 competing drugs or other therapies that are or may become available; |

| · | our expectations with respect to future growth                                                
 and investments in our infrastructure, and our ability to effectively manage any such growth; |

| · | the size and potential growth of the markets                                                                
 for any of our product candidates, and our ability to capture share in or impact the size of those markets; |

| · | the benefits of our product candidates; |

| · | the potential market growth and market and industry 
 trends;                                             |

| · | maintaining collaborations with third parties        
 including our partnerships with the CFF and the DoD; |

| · | potential future collaborations with third parties                         
 and the potential markets and market opportunities for product candidates; |

<div align='center'>11</div>

| · | our ability to achieve our vision, including                     
 improvements through engineering and success of clinical trials; |

| · | our ability to meet anticipated milestones in        
 the development and testing of the relevant product; |

| · | our ability to be a leader in the development 
 of phage-based therapeutics;                  |

| · | the expected use of proceeds from the $26.2 million 
 DoD award;                                          |

| · | the effects of government regulation and regulatory                                                                                       
 developments, and our ability and the ability of the third parties with whom we engage to comply with applicable regulatory requirements; |

| · | the accuracy of our estimates regarding future                              
 expenses, revenues, capital requirements and need for additional financing; |

| · | our expectations regarding future planned expenditures; |

| · | our ability to achieve and maintain effective                                                       
 internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act; |

| · | our ability to obtain, maintain and successfully                                                                  
 enforce adequate patent and other intellectual property protection of any of our products and product candidates; |

| · | our ability to protect our intellectual property, 
 including pending and issued patents;             |

| · | our ability to operate our business without infringing 
 the intellectual property rights of others;            |

| · | our ability to advance our clinical development 
 programs;                                       |

| · | the effects of ongoing conflicts between Ukraine                                                               
 and Russia and in the Middle East, the recent and potential future bank failures or other geopolitical events; |

| · | the potential